Skip to main content
Article thumbnail
Location of Repository

Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)

By Gerhard Kluger and Bettina Bauer


Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change −42.5% vs +1.4% with placebo) and total seizures (−32.1% vs −11.7% with placebo), accompanied by significantly higher responder rates. These results are comparable with findings reported for other AEDs in randomized, controlled clinical trials in patients with LGS. Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability. The most frequently reported adverse events from a pooled safety database evaluating short- and long-term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue (13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile and is a promising candidate for the adjunctive therapy of LGS

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). [online].
  2. (1999). A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome.
  3. (1998). A pharmacokinetic evaluation of rufinamide in elderly and younger subjects [abstract].
  4. (2000). A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf,
  5. (1989). Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy.
  6. (1996). Committee on Safety of Medicines.
  7. (1989). Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome.
  8. (2005). Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut Syndrome (LGS): A multicenter, randomized, double-blind, placebocontrolled parallel trial [abstract].
  9. (2004). Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and
  10. (1993). Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox Gastaut syndrome.
  11. (2006). Epilepsy in children.
  12. (2003). Epileptic encephalopathies: a brief overview.
  13. (1996). Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro [abstract].
  14. (2003). Increased QT dispersion in epileptic children.
  15. (1995). Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res,
  16. (2004). Is there any future for felbamate treatment?
  17. (2003). Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol,
  18. (1996). Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers [abstract].
  19. (2005). Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome [abstract]. Epilepsia, 46(Suppl 6):408(1356).
  20. (2005). Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut Syndrome [abstract].
  21. (1998). Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy [abstract].
  22. (1994). Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400–1200 mg.
  23. (2005). Population pharmacokinetic drug–drug interaction analyses of rufinamide studies in patients with epilepsy [abstract].
  24. (2001). Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference. Epilepsy Res,
  25. (1999). Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference.
  26. (1996). Progress report on new antiepileptic drugs: a summary of the third Eilat conference. Epilepsy Res,
  27. (2006). Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Poster presented at the 7th European Congress on Epileptology,
  28. (2005). Short-term and long-term safety of rufinamide in patients with epilepsy [abstract].
  29. (1998). Single center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on
  30. (2005). The anticonvulsant profile and tolerability of rufinamide in mice and rats [abstract].
  31. (2005). The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis.
  32. (1998). The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos,
  33. (2005). The Influence of rufinamide on sodium currents and action potential firing in rodent neurons [abstract].
  34. (2003). Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.